吸入噻托溴铵治疗慢性阻塞性肺疾病的疗效研究

目的：观察噻托溴铵粉吸入剂治疗稳定期慢性阻塞性肺疾病的有效性及安全性。方法：对2010年1月一2010年12月在本院就诊的60例稳定期COPD患者随机分成两组，对照组接受口服茶碱缓释片治疗，治疗组接受噻托溴铵粉吸入剂治疗。结果：治疗组与对照组治疗后28天FEV1改善率相互比较，差异有统计学意义（P〈0．05）；治疗组与对照组治疗后（d28）以及随访期（疗后第3个月、第6个月）圣·乔治呼吸疾病问卷调查比较，总评分差异均有统计学意义（P〈0．05）；治疗组与对照组治疗后（d28）的6MwT，差异有统计学意义（P〈0．05）；两组患者随访期AECOPD发病次数，有统计学差异（P〈0．05）；两组患者的不良反应相互比较，无统计学意义（P〉0．05）。结论：噻托溴铵粉吸入剂治疗慢性阻塞性肺疾病（COPD）疗效确切和可靠，值得临床推广。

Analysis of Curative Effect of Inhalation of Tiotropium Bromide on the Treatment of Chronic Obstructive Pulmonary Disease

Objective： To explore the clinical effect and safety of Tiotropium Bromide Powder for Inhalation in the treatment of chronic obstructive pulmonary disease. Methods： 60 cases with COPD from January to December 2010 were divided randomly into two groups, the control group was treated with Theophylline Sustained-release tablets while the treating group was treated with Tiotropium Bromide Powder for Inhalation. Results： There was statistically significant difference in the rate of FEV 1 improvement after the treatment for 28 days （P〈0.05）; It was statistical to compare the total score of St. George questionnaire after accepting treatment for 28 days, three months and six months （P〈0.05）; there was statistical meaning to compare the 6MWT after accepting treatment for 28 days and recurrence rate and death rate during the follow-up period between the two groups （P〈0.05）; there was no statistical meaning to compare the side effects between the two groups （P〉0.05）. Conclusion： Tiotropium Bromide Powder for Inhalation can be safely and effectively used in chronic obstructive pulmonary disease, worthy of promotion and application.